SHH and medulloblastoma: At the same time, SJMB12 is investigating intensified treatment regimens for patients in higher risk subgroups, including the addition of gemcitabine and pemetrexed for those with high risk Group 3 or Group 4 medulloblastoma and targeted SHH inhibitor therapy for those with SHH-medulloblastoma (Figure 3).